Vaccine Therapy for Patients With Stage III Melanoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2004 by CancerVax Corporation.
Recruitment status was Active, not recruiting
Information provided by:
First received: January 22, 2003
Last updated: June 23, 2005
Last verified: September 2004
This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.
Biological: CancerVax vaccine (CANVAXIN)
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
||Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma
| Estimated Enrollment:
|Ages Eligible for Study:
||18 Years to 80 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Must have Stage III melanoma
- Must have had all clinically-detectable disease surgically removed
- Cannot be taking any medications, or undergoing any therapies which compromise the functioning of your immune system (ie. Some corticosteroids, and certain types of radiation therapy)
- Cannot have HIV or Hepatitis A, B, or C
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00052130
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 22, 2003
||June 23, 2005
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 24, 2014
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas